Lanean...
Emerging drugs for head and neck cancer
INTRODUCTION: Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-t...
Gorde:
| Argitaratua izan da: | Expert Opin Emerg Drugs |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5678969/ https://ncbi.nlm.nih.gov/pubmed/25826749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728214.2015.1031653 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|